KalVista Pharmaceuticals (NASDAQ: KALV) is one of 48 publicly-traded companies in the “Biopharmaceuticals” industry, but how does it weigh in compared to its rivals? We will compare KalVista Pharmaceuticals to related businesses based on the strength of its earnings, institutional ownership, dividends, profitability, risk, valuation and analyst recommendations.
Valuation & Earnings
This table compares KalVista Pharmaceuticals and its rivals revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|KalVista Pharmaceuticals||$1.50 million||-$18.60 million||-3.04|
|KalVista Pharmaceuticals Competitors||$564.12 million||$96.17 million||61.61|
This table compares KalVista Pharmaceuticals and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|KalVista Pharmaceuticals Competitors||-13,603.82%||-109.96%||-27.55%|
Institutional and Insider Ownership
76.1% of KalVista Pharmaceuticals shares are owned by institutional investors. Comparatively, 43.5% of shares of all “Biopharmaceuticals” companies are owned by institutional investors. 49.1% of KalVista Pharmaceuticals shares are owned by insiders. Comparatively, 15.4% of shares of all “Biopharmaceuticals” companies are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
This is a summary of recent recommendations and price targets for KalVista Pharmaceuticals and its rivals, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|KalVista Pharmaceuticals Competitors||137||801||1761||59||2.63|
KalVista Pharmaceuticals currently has a consensus target price of $27.00, suggesting a potential upside of 176.92%. As a group, “Biopharmaceuticals” companies have a potential upside of 11.23%. Given KalVista Pharmaceuticals’ stronger consensus rating and higher probable upside, research analysts plainly believe KalVista Pharmaceuticals is more favorable than its rivals.
KalVista Pharmaceuticals beats its rivals on 7 of the 11 factors compared.
KalVista Pharmaceuticals Company Profile
KalVista Pharmaceuticals, Inc., formerly Carbylan Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The Company has developed a portfolio of small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME). The Company is developing a plasma kallikrein inhibitor, which is administered directly into the eye. The Company is engaged in advancing several product candidates developed from its portfolio into early clinical trials. The Company is progressing additional oral candidates towards regulatory preclinical studies. The Company’s HAE product candidate, KVD818, is an inhibitor of plasma kallikrein. The Company has initiated clinical testing of KVD818 in a Phase I clinical trial. It has completed an open-label single ascending dose Phase I trial in DME patients with KVD001.
Receive News & Ratings for KalVista Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KalVista Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.